Our Leadership Team has a broad range of experience and is responsible for managing the business on a day-to-day basis.
Chief Executive Officer
Louise Makin, MA, PhD (Cantab), MBA, joined BTG as Chief Executive Officer in October 2004 and she is a non-executive director of Intertek Group plc and a Trustee of the Outward Bound Trust.
From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998.
Chief Financial Officer
Rolf Soderstrom, BA, ACA, joined BTG as Chief Financial Officer in December 2008 from Protherics PLC, where he was Finance Director from August 2007.
From 2004, he was a Divisional Finance Director of Cobham plc, managing a portfolio of businesses across Europe and the USA. From 2000 he was a Director of Corporate Finance at Cable & Wireless plc. Prior to this, he worked in the Corporate Recovery and Corporate Finance Department of PricewaterhouseCoopers after qualifying as a Chartered Accountant.
Executive Vice President, US
Matthew Gantz joined BTG in February 2009. He is Executive Vice President, US, with responsibility for BTG's global specialty pharmaceuticals business and administrative oversight for US business operations. He is also a non-executive director of Swedish Orphan Biovitrum. Prior to BTG, Matthew was Founder and CEO of Acureon Pharmaceuticals, a specialty pharmaceutical company focused in the hospital areas of infectious diseases, transplant and ICU. Prior to Acureon, he was the President and CEO of Hydrabiosciences Inc, a privately held biotechnology company developing novel, ion channel medicines in the pain and cardiovascular area. From 2000 to 2003, Matthew was the VP Europe for Chiron’s Biopharmaceutical Division where he was directly responsible for $100+ million Infection Disease and Oncology business. From 1996 to 2000 he was the GM for PathoGenesis Europe before the company was acquired by Chiron. Prior to Chiron/PathoGenesis, Matthew held a variety of US sales and marketing roles at Abbott Laboratories Diagnostics Division. Matthew served as an infantry officer in the US Marine Corps, earned his MBA from Harvard and his undergraduate degree from Princeton University.
Head of Manufacturing and Supply
Anthony Higham joined BTG in January 2011 with responsibility for leading all manufacturing operations across global sites in the USA, Australia and the UK. He joins following a period spent as an independent industry consultant. He has previously held a number of international, senior Operational and Site Leadership roles at SmithKline Beecham, GlaxoSmithKline and Aesica Pharmaceuticals. Anthony has a BSc in Biological Sciences from Bangor University and an MSc in Manufacturing Systems Engineering from Hatfield Polytechnic.
Guenter R Janhofer
Chief Medical Officer and Head of Development
Guenter R Janhofer joined BTG in March 2009 as Head of Development. In 2011 he also became BTG's Chief Medical Officer. Guenter has more than 25 years of experience in the pharmaceutical industry across all phases of clinical development from Phase I to end-stage life-cycle management and across a wide variety of therapeutic areas, including cardiovascular, metabolic, neuroscience, infectious diseases, respiratory, osteoporosis and oncology. Having started as Medical Director of Desitin Pharmaceuticals in Hamburg, Germany, he later served Merck & Co., Inc. in functions of growing complexity and scope, both at the subsidiary and at the headquarters’ level. He most recently served as Vice President of Global Medical and Scientific Affairs and has been instrumental of bringing Internet technology to Merck’s clinical development process. Guenter holds an MD degree from Hamburg University, PhDs in Climatology and Medicine from the University of Bochum and a post-doc degree (Habilitation) from the University of Technology in Berlin, where he is a faculty member at the School of Public Health.
Group Director of Finance
Duncan Kennedy joined BTG in December 2005 as Group Financial Controller and joined the Leadership Team in April 2012 following appointment to his current role. He has management responsibility for the global finance function, supporting the CFO, and was a member of the acquisition and subsequent integration teams for the acquisitions of Protherics PLC in 2008 and Biocompatibles International plc in 2011.
Prior to joining BTG, Duncan spent six years in the group finance function of Wembley plc, an international leisure group, gaining wide-ranging experience in all aspects of listed company financial reporting and significant involvement in corporate transactions. Duncan qualified as a Chartered Accountant at Arthur Andersen and holds a BSc in Mathematics from Durham University.
Head of Business Development
Richard Mason joined BTG in April 2009 as Head of Business Development. He joined from venture capital firm Advent Venture Partners where, as Executive-in-Residence, he undertook CEO assignments at portfolio life sciences companies, both listed and private. Previously Richard was Senior Vice President Business Development at Cambridge Antibody Technology plc. Richard qualified in medicine from the Medical College of St. Bartholomew’s Hospital, University of London and subsequently worked for the NHS in internal and emergency medicine at several London teaching hospitals. He is a member of the Royal College of Physicians and also holds a BSc in Immunology from University College London and an MBA from the Judge Business School, University of Cambridge, where he is currently an Honorary Fellow. He is on the board of the monoclonal antibody journal mAbs.
Head of Varisolve®
Paul McCubbin, MA, D Phil, ACA, joined BTG in 2001, working initially in the Corporate Venturing team and became head of that business unit in 2004. Since then he has taken on a succession of operational roles at BTG. He was appointed General Manager of Varisolve®, BTG’s experimental treatment for varicose veins, in 2009 and became the Head of Varisolve® in April 2013, following submission of a new drug application in the US.
Prior to joining BTG, Paul was the Finance Director of Profiad Limited, a CRO spun-out of GlaxoWellcome. Previously, he led the corporate finance team in Ernst & Young’s life sciences group, advising early stage companies on strategy, partnering and fundraising. Paul qualified as a chartered accountant in 1995, whilst working in the corporate recovery and turnaround divisions at Arthur Andersen.
Paul gained his degree and doctorate in biological sciences from the University of Oxford and worked as an MRC post-doctoral research fellow at Manchester University.
General Counsel & Company Secretary
Paul Mussenden joined BTG in 2000 and is responsible for all aspects of the group’s legal affairs. Paul is also the Company Secretary, providing governance advice and other support to the Board. In addition, Paul is responsible for the management of the Intellectual Property, Healthcare Compliance and Environmental, Health & Safety groups. Prior to joining BTG, Paul was an adviser in the Equity Markets Group at the London Stock Exchange with a focus on high-tech and healthcare companies. He entered the legal profession with the international private practice firm Norton Rose, focusing on M&A, corporate finance and commercial transactions. Paul has over 15 years of experience advising companies in the healthcare sector and holds a BSc and PhD in molecular biology and microbial physiology.
Head of HR & IT
Yvonne Rogers joined BTG in December 2008 following the merger of BTG and Protherics. She joined Protherics in November 2003 to build Protherics’ Human Resources and Learning and Development activities across the global company. Since April 2010 she has taken on global responsibility for IT. Before joining Protherics she held senior roles at Troika UK Limited, KPMG, The Mitsubishi Bank and House of Fraser. A graduate of the Chartered Institute of Personnel and Development, she has spent over 20 years as a generalist Human Resources professional.
Chief Technical Officer, Interventional Medicine
Peter Stratford joined BTG in January 2011, following the acquisition of Biocompatibles. Peter joined Biocompatibles in 1990 and was appointed to the Board in 2002. He took the role of Group Director Research and Development in 1998 and transitioned the Group to the current oncology products focus. He joined the Cardiovascular Division Management Team at its creation in 1993, after completion of development work in contact lens application. Peter has a BSc in Chemistry, an MSc in Polymer Synthesis and a PhD in Pharmaceutical Synthesis.
Chief Commercial Officer, Interventional Medicine
John Sylvester joined BTG in January 2011, following the acquisition of Biocompatibles. John joined Biocompatibles in 2005 and was appointed to the Board in the same year. His career covers a series of commercial roles for Rio Tinto Zinc plc, ICI plc and English China Clays where he was General Manager for their European and Asian Operations. Previously he was with Baxter Healthcare where he was VP Marketing for their European Medication delivery business.
Our Board of Directors is responsible for corporate governance and ultimately accountable for our activities, strategy and performance.